凝血酶原复合物对比血浆管理心脏术后凝血病的倾向评分匹配研究
单中心2012-2016年6362例体外循环心脏手术患者中,1151例(18.2%)仅用血浆、204例(3.2%)用凝血酶原复合物(PCC,联合或不联合血浆)管理凝血病;倾向评分匹配各117例后,PCC组避免红细胞输注的比值比为2.4倍(95%CI 1.2-4.8),大输血和难治性出血发生率接近显著降低,不良事件谱相似。
要点
- PCC组避免围术期红细胞输注的OR为2.4倍(95%CI 1.2-4.8)。
- 大输血OR 0.58(95%CI 0.33-1.0)、难治性出血OR 0.49(95%CI 0.24-1.03),接近显著降低。
- 两组不良事件谱相似,但PCC临床应用仍需多中心随机试验确定风险获益。
核心结论
- 探索性研究提示,PCC作为多层面凝血管理策略的一部分可能具有血液保护效应。
- PCC纳入临床实践前仍需通过多中心随机试验确定其风险获益特征。
研究设计与样本
- 单中心2012至2016年体外循环心脏手术患者的回顾性比较研究,共6362例。
- 1151例(18.2%)仅接受血浆,204例(3.2%)接受PCC(联合或不联合血浆)。
- 采用倾向评分匹配获得组间平衡,匹配后每组117例。
主要发现
- 匹配后PCC组避免红细胞输注的比值比为2.4倍(95%CI 1.2-4.8)。
- 大输血(超过9单位红细胞)OR 0.58(95%CI 0.33-1.0),难治性出血(需因子VIIa)OR 0.49(95%CI 0.24-1.03),接近显著降低。
- 两组不良事件谱相似;PCC组总体患者风险特征更高。
关键数值与推荐
- 主要结局为避免围术期红细胞输注,PCC组OR 2.4(95%CI 1.2-4.8)。
- 大输血定义为超过9单位红细胞,OR 0.58(95%CI 0.33-1.0)。
- 难治性出血定义为需因子VIIa,OR 0.49(95%CI 0.24-1.03)。
临床怎么用
- 心脏术后凝血病可考虑将PCC纳入多层面凝血管理策略以可能减少红细胞输注。
- 因证据来自探索性单中心研究,PCC常规应用应等待多中心随机试验结果。
局限性
- 单中心回顾性研究,PCC组总体风险特征更高。
- 研究为探索性,样本量有限(匹配后每组117例)。
- PCC临床应用需多中心随机试验确定风险获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: An important cause of coagulopathy in cardiac surgery is impaired thrombin generation. While plasma is often used to correct this element of the coagulopathy, studies in vitro suggest that prothrombin complex concentrates (PCCs) might be more effective. Comparative data, however, are scant. METHODS: We compared the outcomes of those who received only plasma with those who received PCCs (with or without plasma) for management of coagulopathy in patients who underwent cardiac surgery with cardiopulmonary bypass at a single institution from 2012 to 2016. Propensity score matching was used to obtain between-group balance. Primary outcome was avoidance of perioperative red cell transfusions. Other outcomes were incidence of massive transfusion (more than nine red cell units), refractory bleeding (requiring factor VIIa), and adverse events. RESULTS: Of 6362 patients, 1151 (18.2%) received plasma without any PCCs, and 204 (3.2%) received PCCs, either with (n=125) or without plasma (n=79). Overall, patient risk-profile was higher in the PCCs group. In a well-balanced propensity score match that included 117 patients per group, the odds ratio (OR) for red cell avoidance was 2.4-fold [95% confidence interval (CI) 1.2-4.8] higher in the PCCs group. Massive transfusion (OR 0.58; 95% CI 0.33-1.0) and refractory bleeding (OR 0.49; 95% CI 0.24-1.03) incidences were almost significantly lower in the PCCs group. The adverse event profiles were similar. CONCLUSIONS: Our exploratory study suggests that the use of PCCs as part of a multifaceted coagulation management strategy may have blood-sparing effects. Their incorporation into clinical practice, however, must await determination of their risk-benefit profile via multicentre randomised trials.
引用
- Fitzgerald J, Lenihan M, Callum J, et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. Br J Anaesth. 2018. PMID: 29661410. doi:10.1016/j.bja.2018.02.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。